Nature Communications (Jan 2020)
YAP1 mediates survival of ALK-rearranged lung cancer cells treated with alectinib via pro-apoptotic protein regulation
- Takahiro Tsuji,
- Hiroaki Ozasa,
- Wataru Aoki,
- Shunsuke Aburaya,
- Tomoko Yamamoto Funazo,
- Koh Furugaki,
- Yasushi Yoshimura,
- Masatoshi Yamazoe,
- Hitomi Ajimizu,
- Yuto Yasuda,
- Takashi Nomizo,
- Hironori Yoshida,
- Yuichi Sakamori,
- Hiroaki Wake,
- Mitsuyoshi Ueda,
- Young Hak Kim,
- Toyohiro Hirai
Affiliations
- Takahiro Tsuji
- Department of Respiratory Medicine, Graduate School of Medicine, Kyoto University
- Hiroaki Ozasa
- Department of Respiratory Medicine, Graduate School of Medicine, Kyoto University
- Wataru Aoki
- Division of Applied Life Sciences, Graduate School of Agriculture, Kyoto University
- Shunsuke Aburaya
- Division of Applied Life Sciences, Graduate School of Agriculture, Kyoto University
- Tomoko Yamamoto Funazo
- Department of Respiratory Medicine, Graduate School of Medicine, Kyoto University
- Koh Furugaki
- Product Research Department, Kamakura Research Laboratories, Chugai Pharmaceutical Co., Ltd
- Yasushi Yoshimura
- Product Research Department, Kamakura Research Laboratories, Chugai Pharmaceutical Co., Ltd
- Masatoshi Yamazoe
- Department of Respiratory Medicine, Graduate School of Medicine, Kyoto University
- Hitomi Ajimizu
- Department of Respiratory Medicine, Graduate School of Medicine, Kyoto University
- Yuto Yasuda
- Department of Respiratory Medicine, Graduate School of Medicine, Kyoto University
- Takashi Nomizo
- Department of Respiratory Medicine, Graduate School of Medicine, Kyoto University
- Hironori Yoshida
- Department of Respiratory Medicine, Graduate School of Medicine, Kyoto University
- Yuichi Sakamori
- Department of Respiratory Medicine, Graduate School of Medicine, Kyoto University
- Hiroaki Wake
- Division of System Neuroscience, Graduate School of Medicine, Kobe University
- Mitsuyoshi Ueda
- Division of Applied Life Sciences, Graduate School of Agriculture, Kyoto University
- Young Hak Kim
- Department of Respiratory Medicine, Graduate School of Medicine, Kyoto University
- Toyohiro Hirai
- Department of Respiratory Medicine, Graduate School of Medicine, Kyoto University
- DOI
- https://doi.org/10.1038/s41467-019-13771-5
- Journal volume & issue
-
Vol. 11,
no. 1
pp. 1 – 16
Abstract
Relapse is a limitation for the efficacy of the anaplastic lymphoma kinase (ALK)-inhibitor alectinib in ALK-rearranged lung cancer. Here, the authors show that YAP1 activation upon alectinib treatment leads to therapy resistance and that inhibiting both YAP1 and ALK leads to longer tumor remission in mice.
